Proteus Digital Health

About Proteus Digital Health

Armed with more than 300 issued patents and led by some of the brightest minds in technology, pharmaceuticals and healthcare, we’ve invented Digital Medicine, a new category that measures medication treatment effectiveness, helps physicians improve clinical outcomes and patients reach health goals. Together, with leading health systems and pharmaceutical companies, we’re bringing this new digital solution to healthcare providers, thereby increasing access to better insight, optimized therapies and lower costs.

Press Office

For product images, video footage and interview requests, please contact the Proteus Press Office. Media requests only.

Phone Press: +1 650 637 6225

Upcoming Events

Press Releases

News Stories

Our executive team and board of directors guide Proteus based on their depth of expertise across life sciences, consumer technology and capital markets.

Andrew Thompson

Co-Founder, CEO

Andrew Thompson is co-founder, president and chief executive officer of Proteus Digital Health. His vision for Digital Medicine is focused on expanding global access to care, dramatically increasing the value delivered by drugs and creating a sustainable model for innovation that leverages the cell phone in everyone’s pocket.

Andrew serves on the World Economic Forum Technology Pioneers selection committee and he is also a Co-Founder and Board member of Summit Schools, a leading Charter High School organization with a unique digital platform.  Andrew is active in digital humanities innovation with Stanford University and Cambridge University and a Co-Founder of Parker Library Online – the leading destination for digital medieval studies.

He holds masters degrees in Engineering (Cambridge), Education (Stanford) and Business (Stanford GSB) and has a successful 25 year track record starting and building technology based healthcare companies in Silicon Valley.

George Savage, M.D.

Co-Founder, Chief Medical Officer

George Savage is chief medical officer and co-founder of Proteus Digital Health, and formerly the company’s vice president of research and development. He sees Digital Medicine as an invaluable collaboration platform for patient and physician, integrating information about a patient’s response to therapy directly into everyday healthcare.

George is focused on developing the clinical and economic evidence needed to secure global regulatory approvals and spur widespread adoption of Proteus’s ingestible sensor platform. He serves on the board of the California Life Sciences Association, the Boston University College of Engineering advisory council, and in 2016 was elected a Fellow of the American Institute for Medical and Biological Engineering.

George holds a B.S. in biomedical engineering from Boston University, an M.D. from Tufts University School of Medicine, and an M.B.A. from Stanford University Graduate School of Business. He completed postgraduate training in surgery at the University of Massachusetts and is licensed to practice medicine in California. George has a successful 27-year track record of starting and developing technology-based healthcare companies in Silicon Valley.

Mark Zdeblick, Ph.D.

Co-Founder, Chief Technologist

Mark Zdeblick is chief technologist and co-founder of Proteus Digital Health, and leads the group innovating on our technology. Previously, Mark served as the chief technology officer for the optical switch group at K2 Optronics and served as founder and chief technology officer of Redwood Microsystems.

Mark holds a B.S. in civil engineering and a B.A. in architecture, both from the University of Illinois, and an M.S. in aeronautics and astronautics and Ph.D. in electrical engineering from Stanford University.

Uneek Mehra

Chief Financial Officer

As Chief Financial Officer, Uneek is responsible for accounting, financial reporting, budgeting, business planning and forecasting. He is also responsible for the Facilities, IT and People teams. Prior to joining Proteus, Uneek had extensive experience in senior finance leadership roles with Novartis, IBM and Citibank. At Novartis, Uneek worked in roles with increasing responsibilities in the Corporate Finance, Commercial Finance, Corporate Business Development and Treasury departments across the US, Switzerland and China. He also served as CFO of two of the largest specialty Medicines Franchises within the Novartis US business.

Uneek has a MBA in strategy and leadership from IMD, Lausanne, Switzerland as well as a Masters in Finance and a Bachelors in Engineering from premier universities in India.

Molly O'Neill

Chief Commercial Officer

Molly O’Neill is chief commercial officer of Proteus Digital Health, where she leads partnerships with major health systems, payers and key provider customers. Molly is a healthcare industry veteran with a 30+ year track record of developing and executing growth strategies to increase market share and revenues. Prior to joining Proteus, she was the Senior Vice President of business development at Tenet Healthcare, a diversified healthcare services company. Molly has also held leadership roles at Duke Medicine, Partners Healthcare, Inova Health System, Ascension Health Care Network, a joint venture between Ascension Health Alliance and Oak Hill Capital Partners.

Having worked across major provider and healthcare service companies, Molly believes the greatest potential of Digital Medicines is in transforming a patient’s engagement with their physicians, their families and most importantly their own health. Molly is a member of the board of World Care International Inc. and holds degrees from the Medical College of Virginia and Virginia Commonwealth University.

David O'Reilly

Chief Platform Officer

David O’Reilly is chief platform officer of Proteus Digital Health and leads the company’s Digital Medicine development, manufacturing, corporate development and corporate strategy areas. Prior to joining Proteus, David spent over 15 years starting and building life sciences companies focused on novel platforms for drug discovery and personalized medicine. He was President of Catalyst Biosciences, Chief Business Officer and member of the founding management team at Iconix Biosciences, and Head of Corporate Development for ARIAD Pharmaceuticals (where he was also the general manager of a subsidiary company, ARIAD Gene Therapeutics). He began his career as a management consultant to health care and biotechnology companies at L.E.K. Consulting.

David is a graduate of Wesleyan University, where he was named the Gilbert Clee Scholar, and Harvard Business School, where he received an MBA with Distinction.

Sean Handel

Senior Vice President Product

Sean Handel leads product management, design and software engineering at Proteus Digital Health. Most recently, Sean was Senior Vice President of Product at Swrve, a mobile engagement platform that helps major brands to engage their customers via their mobile apps. Previously, Sean was SVP Product Management and Marketing at Epocrates where he lead product initiatives from an early stage through the company’s IPO and subsequent acquisition by athenahealth. This included offerings for providers, health systems, health plans, and pharmaceutical companies. Epocrates became the number one brand in healthcare technology for physicians—at its peak, Epocrates was used by more than 50% of all physicians in the US and 1.4 million healthcare providers overall.

Sean holds Bachelor of Arts and Master of Science degrees in Computer Science from Northwestern University. He also advises technology startups in the healthcare technology and sports & fitness wearables areas.

Neela Paykel

Head of Legal Affairs and Compliance

Neela Paykel is head of legal affairs and compliance at Proteus Digital Health. Prior to joining Proteus, Neela was assistant general counsel and practice group leader at Genentech where she served as the lead attorney providing legal support to the managed markets business unit. She advised on a broad range of managed care, healthcare law, privacy, antitrust and FDA promotional issues. Prior to Genentech, Neela was at CVS Caremark serving as the lead counsel for health plan PBM business and was an Associate Counsel at Blue Shield.

Neela is a graduate of Wesleyan University with a Bachelor of Arts in International Business Administration and received her Juris Doctorate degree from George Washington University.

Our executive team and board of directors guide Proteus based on their depth of expertise across life sciences, consumer technology and capital markets

Jonathan Symonds, CBE


Jon Symonds, CBE, is Chairman of HSBC Bank Plc, Chairman of the Supervisory Board of Innocoll AG and Non-executive Director of Genomics England.

Formerly, Symonds was Chief Financial Officer of Novartis, Partner and Managing Director of Goldman Sachs and Chief Financial Officer of AstraZeneca Plc.

Symonds has served on the Proteus Board of Directors since June of 2014 and now advises Proteus on strategy, financial management and corporate governance in his role as Chairman.

Shumeet Banerji, Ph.D.

Board Member

Shumeet Banerji is founder and partner of Condorcet, LP an investment and advisory firm. In 2013, Banerji retired from Booz & Company Inc. having served as its founding Chief Executive Officer.

Formerly, he held leadership roles at Booz, Allen & Hamilton in India, the U.K., Europe and globally, where he advised public and private sector entities at the Board level. He serves on the Board of HP, Inc. and Innocoll, AG.

Banerji provides oversight on Proteus’ corporate strategy and operational performance, among other topics of critical importance.

Robert Epstein, M.D., M.S.

Board Member

Dr. Robert Epstein was most recently president of the Medco-UBC Division and chief R&D officer of Medco Health Solutions, Inc.

Dr. Epstein is the former president of the International Society of Pharmacoeconomics and Outcomes Research, and has served on the Board of Directors of the Drug Information Association.

He has published more than 50 peer-reviewed medical articles and book chapters, and serves as a reviewer for several influential medical journals.

Frank Fischer

Board Member

Frank Fischer has more than 25 years of senior management experience in the medical device industry.

The president and CEO of the biomedical device company NeuroPace, he has served on the company’s board since 1998 and joined the company as its chief executive officer in January 2000.

Frank continues to serve on the boards of several privately held medical device companies.

Alan J. Levy, Ph.D.

Board Member

Alan Levy is a venture partner with Frazier Healthcare Ventures and has over 30 years of senior management experience in the medical device industry.

He serves on the board of Intuitive Surgical, a publicly held company, and several other privately held medical device firms.

Myrtle Potter

Board Member

Myrtle is CEO of Myrtle Potter and Company. A best-selling author, Myrtle has dedicated three decades to serving the healthcare needs of millions of consumers.

She serves on the board of Everyday Health, Liberty Mutual and is on the board of Trustees of the University of Chicago. Myrtle was president and chief operating officer of Genentech, president at Bristol-Myers Squibb and a vice president at Merck.

Ryan Schwarz

Board Member

Ryan Schwarz is a managing director at The Carlyle Group where he leads the healthcare investing practice for the company’s U.S. Venture & Growth Capital Group, specializing in medical devices, medical technology and healthcare information technology.

Ryan serves on the boards of AcuFocus, Lipsonix, NeoVista, Cellutions and PixelOptics.

Charles Songhurst

Board Member

Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He runs an investment portfolio and the Songhurst Group which holds asset in a variety of private companies.

Previously, Charles ran corporate strategy for Microsoft and focused on partnering and M&A.

Immanuel Thangaraj

Board Member

Immanuel Thangaraj is a managing director at Essex Woodlands, a leading health care venture capital and growth equity company.

With over 15 years of experience in operations and venture capital, he currently serves on the boards of CBR Systems, Acura Pharmaceuticals, Clear Vascular, Medlogics, and Sound ID.

Our Partners

We have engaged license agreements with strategic partners to build our patented ingestible-sensor technology into new Digital Medicine offerings.


Proteus has had a strategic partnership with Otsuka since 2012. Otsuka and Proteus are partnering to combine Otsuka’s ABILIFY® (aripiprazole) with the FDA-cleared Proteus® ingestible sensor embedded in a single tablet at point of manufacture. This is the first time the FDA cleared Proteus® ingestible sensor will be integrated with an approved medication as a combination product to measure medication-taking patterns and physiologic response. FDA-approved medication (Abilify) has been combined with a sensor within the medication tablet (the Proteus ingestible sensor) to measure actual medication-taking patterns and physiological response.


Proteus has had a strategic partnership with Novartis since 2009.